What is Inhibrx Biosciences, Inc.?
, a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.02B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 42,000 shares $221k | 1648,440 shares $4.9M |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |